Millions of Medicare enrollees who take prescription drugs are likely to see their monthly plan premiums climb for 2027, and the reason has nothing to do with the drugs themselves. A temporary federal subsidy that has been holding down the cost of stand-alone Part D drug plans is scheduled to end at the close of this year, removing a cushion that trimmed premiums in 2026. For retirees on fixed incomes, the change makes the annual renewal letter arriving this fall more important than usual, because a plan that auto-renews could carry a noticeably higher price tag.
The Part D price cushion that ends December 31
The subsidy at the center of the increase is the Part D Premium Stabilization Demonstration, a program the federal government launched at the start of 2025 to keep drug-plan premiums from spiking as major changes to the Medicare drug benefit took effect. Those changes, including a new cap on annual out-of-pocket drug costs, shifted more expense onto insurers, and the demonstration offset part of that pressure by paying plans to hold premiums down. It reduced the average stand-alone drug-plan premium by roughly $16 a month in 2026.
That demonstration is set to expire on December 31, 2026, and will not continue into the new plan year. When the payments stop, the cost they were absorbing does not disappear; it moves back toward enrollees in the form of higher premiums. Independent analysts and the Centers for Medicare & Medicaid Services both expect a large share of stand-alone drug-plan enrollees to pay more in 2027, though the size of the increase will vary widely from one plan to the next.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. The free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
What the renewal letter will tell enrollees this fall
Every Medicare drug plan and Medicare Advantage plan is required to send enrollees an Annual Notice of Change, the document that spells out how the plan’s costs and coverage will differ in the coming year. Plans must get that notice to members by September 30, which means the letters explaining 2027 premiums, deductibles, and drug coverage should be in hand well before any decisions are due.
The temptation is to set the notice aside, because doing nothing keeps the current plan in place. That is precisely the risk this year. A plan left to renew automatically will carry whatever new premium and cost structure the notice describes, and with the stabilization subsidy gone, that structure may be meaningfully more expensive than the one the enrollee signed up for a year earlier. Reading the notice line by line, and comparing the new premium against what the household paid in 2026, is the only way to know whether an auto-renewal is a good deal or a quiet cost increase.
How the Annual Enrollment window works
The chance to act on that information comes during Medicare’s Annual Enrollment Period, which runs from October 15 through December 7. During those weeks, enrollees can switch from one drug plan to another, move between Original Medicare with a drug plan and Medicare Advantage, or drop or add coverage, with the choice taking effect January 1. Plan-specific premiums for 2027 are generally published in mid-to-late September, so the notice and the public plan-comparison data should both be available before the window opens.
Shopping matters more in a year when premiums are moving. Because the loss of the subsidy will not hit every plan equally, a household’s current plan may see a large jump while a competing plan covering the same medications rises less or holds steady. Comparing plans on the official Medicare Plan Finder, using an actual list of the drugs a person takes and the pharmacies they use, can surface a lower total cost that a straight auto-renewal would miss. An analysis of what to expect in the 2027 enrollment period notes that the premium landscape is shifting enough that even satisfied enrollees should re-check their options rather than assume last year’s choice is still the best one.
What is not changing for 2027
The consumer protections that took effect under the recent Medicare drug reforms remain in place for 2027, which softens the picture somewhat. The $2,000 annual cap on out-of-pocket spending for covered drugs continues, as does the $35 monthly cap on a covered month’s supply of insulin, and Medicare’s authority to negotiate prices on certain high-cost drugs is unchanged. In other words, the ceiling on what a beneficiary can be forced to spend out of pocket in a year is holding even as monthly premiums drift upward.
That distinction is worth keeping in mind while comparing plans. A plan with a somewhat higher premium may still be the better financial choice for someone with significant drug costs, because the out-of-pocket cap limits total exposure regardless of premium. The right comparison is total expected annual cost, premium plus deductible plus expected out-of-pocket spending, not premium alone.
A practical checklist before January 1
The steps are straightforward and time-limited. Enrollees should open the Annual Notice of Change when it arrives rather than filing it unread, note the 2027 premium and compare it to the current one, and list their current medications and pharmacies for use in the Plan Finder. Anyone who sees a premium increase they cannot comfortably absorb has until December 7 to move to a cheaper plan that still covers their drugs. Households that want help can turn to their State Health Insurance Assistance Program, a free counseling service that reviews plans without selling anything. The one choice to avoid is the passive one, letting a more expensive plan renew simply because the letter went unopened.
This article was researched and drafted with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- The ideal retirement withdrawal rate so your savings actually last
- Bank statements: how long to keep them and when to toss them
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
